Clinical Trial Update: Adaptation Dose of Enoxaparin in Moderate Renal Failure Patients With Acute Coronary Syndrome [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating adapted dosing of enoxaparin in patients with acute coronary syndrome and moderate renal failure has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome
• Renal Failure

Drugs mentioned

• Enoxaparin (enoxaparin sodium)

Snippet

Sponsor: French Cardiology Society | Conditions: Acute Coronary Syndrome, Renal Failure | Phase 4 | Status: COMPLETED